Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dienogest + drospirenone dose-combination study for ovulation inhibition with intentional intake errors
2026-526788-39-00Phase 2Authorised
- Sponsor
- Gedeon Richter Plc
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dienogest and drospirenone in contraception (4 arms), sponsored by Gedeon Richter Plc. Primary endpoint: Ovulation incidence in treatment cycles 1-3. Planned start Oct 2026; status: authorised.
02
Drugs
dienogestdrospirenone
03
Conditions
contraception
Beyond the preview
Go deeper on 2026-526788-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526788-39-00.